Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olorofim PK in Renal Impairment
NCT05200286Phase 1Completed
- Sponsor
- F2G
- Start
- Feb 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olorofim in invasive fungal infection (IFI), invasive aspergillosis (IA), scedosporiosis and 2 more (2 arms), sponsored by F2G. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to the time of the last quantifiable concentration and Maximum Observed Plasma Concentration. Started Feb 2022; status: completed.
02
Drugs
olorofim
03
Conditions
invasive fungal infection (IFI)invasive aspergillosis (IA)scedosporiosislomentosporiosiscoccidioidomycosis
Beyond the preview
Go deeper on NCT05200286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05200286.